LONGs: APWR MIPS ARBA ESPH LOOP
Friday, June 11, 2010
Wednesday, June 9, 2010
Monday, June 7, 2010
Saturday, June 5, 2010
Delcath Liver Tumor System Data Improve
"June 5 (Reuters) - A drug delivery system developed by Delcath Systems Inc (DCTH.O) helped melanoma patients whose cancer had spread to their liver live much longer than patients treated with best available care.
The company, which announced in April that the 93-patient trial was successful, will present the detailed results later on Saturday at a meeting of the American Society of Clinical Oncology in Chicago.
A preliminary summary provided to ASCO earlier showed that patients treated with Delcath's PHP System lived for an average of 245 days before dying or having their cancer get worse. Patients treated with standard drugs survived for an average of 49 days before they died or their tumor growth restarted.
Delcath's system is designed to deliver high doses of the chemotherapy drug melphalan directly to the liver, through the hepatic artery. The drug is very toxic, but not for normal cells in the liver.
The system aims to minimize side effects by filtering the drug out of the blood stream as it leaves the liver, but some of the drug does leak out.
As a result, the major side effect seen in the trial was bone marrow suppression.
Delcath has begun a rolling application for its PHP system at the U.S. Food and Drug Administration and expects to complete the package later this year.
The company has estimated peak annual U.S. sales of $745 million if the system is approved for use in melanoma patients whose cancer has spread to the liver. Use in primary liver cancer as well as metastases from other types of cancer could put the sales potential at $5.6 billion. "
The story just keeps getting better and better.(LONG DCTH since $4's) Congrats to those of you who are still long DCTH with me.
Thursday, June 3, 2010
Wednesday, June 2, 2010
Monday, May 31, 2010
Tuesday, May 25, 2010
$DCTH CEO talks ASCO
NEW YORK (TheStreet) - - Delcath readies phase 3 results for a June 5th announcement for chemo delivery system that improves cancer survival. To all DCTH Longs (Must Watch Clip)
Thursday, May 20, 2010
Solar bounce play results!
Market went down nearly 400 points today but solar manage to close in the greens: $STP $YGE $TSL wins. Alert from yesterday(Solar bounce play).
Intraday charts below:
STP
TSL
YGE
Intraday charts below:
STP
TSL
YGE
Wednesday, May 19, 2010
Solar Bounce play
Hammer candlesticks form when a security moves significantly lower after the open, but rallies to close well above the intraday low. The resulting candlestick looks like a square lollipop with a long stick. If this candlestick forms during an advance, then it is called a Hanging Man.- stockcharts.comI bought YGE, STP into the close today for a reversal(bounce play). You can see series of Hammer candlesticks forming in Solar stocks and it is getting way oversold. I am long term bearish on solar (based on the daily chart) but it should be setting up for a quick bounce. Let's take a look on some of these setups.
Disclosures: Long STP YGE for a day or two(most likely one day).
CCME to begin trading on the NASDAQ on June 3rd
Press Release Source: China MediaExpress Holdings, Inc. On Wednesday May 19, 2010, 8:45 am
FUJIAN, China--(BUSINESS WIRE)--China MediaExpress Holdings, Inc. (NYSE Amex: CCME) (“CME” or “Company”), China’s largest television advertising operator on inter-city and airport express buses, today announced that its common stock has been approved for listing on the NASDAQ Global Select Market.
Effective as of the close of trading on June 2, 2010, the Company’s common stock will cease trading on NYSE AMEX. Upon the opening of trading on June 3, 2010, the Company's shares will commence trading on NASDAQ Global Select Market, under the same ticker symbol "CCME".
Mr. Zheng Cheng, CME’s Founder and CEO, noted, “We believe that NASDAQ represents the best fit for our Company and our shareholders. NASDAQ's market maker structure should lead to increased liquidity, an expansion in our shareholder base and, ultimately, to increased shareholder value. In addition it will provide our investors with the best prices and the fastest execution. As the world's largest electronic stock market, NASDAQ promotes innovation and attracts leading growth companies from a diverse group of sectors. CME is one of the very few Chinese companies to qualify for the NASDAQ Global Select Market, which has the highest initial listing standards of any exchange in the world. Out of 136 China-based companies listed on NASDAQ, only 26 companies such as Baidu, CTrip.com International, Shanda Interactive Entertainment and NetEase.com, fulfill NASDAQ Global Select Market requirements. Within only seven months since CME became a public company in October 2009, we have qualified and are making the decision to move to the NASDAQ Global Select Market. This achievement is an important milestone for our Company and we look to the future with confidence.”
Long and Strong!
Monday, May 17, 2010
Thursday, May 13, 2010
Celsion's Phase III ThermoDox HEAT study Recommended for Continuation by Data Monitoring Committee
"COLUMBIA, Md., May 13 /PRNewswire-FirstCall/ -- Celsion Corporation (
The DMC for the HEAT study is comprised of an independent group of medical and scientific experts who are responsible for reviewing and evaluating patient safety and efficacy data. The DMC reviews study data at regular intervals with the charter to ensure patient safety and monitor the quality and overall conduct of the study. The study design and statistical plan for the Phase III ThermoDox trial also incorporates a pre-planned interim efficacy analysis by the DMC after patient enrollment is complete, with the intent to stop the study if there is overwhelming evidence of treatment benefit or a low probability of treatment success.
"We are pleased that the DMC has recommended continuation of the study based on its review of all of the available study data," stated Michael H. Tardugno, President and Chief Executive Officer of Celsion. "The DMC's affirmative review of the 12 Japanese patients enrolled to date is a positive step forward, as it confirms Celsion and Yakult's decision to initiate Phase III trials in Japan. The arrangement, to move directly into Phase III trials was based on previous evidence in primary liver cancer patients, may have shortened our timeline for approval in Japan by two years. With recent acceleration in patient recruitment, and the study now almost 60% enrolled, we are optimistic of a timely completion to enrollment."
Celsion's global Phase III ThermoDox study for primary liver cancer plans to enroll 600 patients and is being conducted under a FDA Special Protocol Assessment (SPA). The study is designed to evaluate the efficacy of ThermoDox in combination with radiofrequency ablation (RFA) when compared to patients who receive RFA alone as the control. The primary endpoint for the study is progression-free survival. Additional information on the Phase III ThermoDox clinical study may be found at www.clinicaltrials.gov."
LONG AND STRONG!! Accumulated more from last week.
Wednesday, May 12, 2010
Tuesday, May 11, 2010
Monday, May 10, 2010
MCGI Setup
Still enjoying my break at the moment. I am going to let the dust settle before I start trading like a maniac. So far this is the only breakout setup that is worth a shot IMHO.
Subscribe to:
Posts (Atom)